Despite a cloud over the industry, these three are still very expensive. Here's why.
How this "Big Pharma" is revolutionizing the fight against cancer and well-positioned for long-term growth.
The cutting edge of a healthcare trend is often a very profitable place to be.
Big Pharma is out with encouraging cancer-survival data and response rates prior to the June ASCO event.
The biotech launches Cabometyx for kidney cancer.
Bristol-Myers' shares touched a 17-year high in April -- can the good times continue?
First quarter earnings could impact trading in this big cap pharmaceutical stock. Here's what you need to know.
Nike, Microsoft, and Bristol-Myers Squibb could be worth owning in any investor's portfolio.
Former partners are set to battle it out in the marketplace.
Here are a few good reasons why ExxonMobil, Bristol-Myers Squibb, and Microsoft would make smart additions to conservative income hunters' portfolios.